The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Funding Opportunities

ALK Positive, LUNGevity Foundation issue RFA for lung cancer research award program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

ALK Positive and LUNGevity Foundation have issued a Request for Application for ALK-positive Lung Cancer Research Awards to be granted in 2022. 

Letters of intent are due by Feb. 23, 2022. For those invited to submit a full application, the due date will be May 9, 2022.

Funded projects are expected to have a direct impact on the outcomes of patients with advanced ALK-positive lung cancer, but innovative proposals that address other unmet needs in the ALK-positive lung cancer space are also invited for submission. 

The ALK-positive award has no geographical restrictions; international researchers may apply. The successful applicant may receive up to $750,000 over an award term of two years.

The Request for Applications is posted on the proposalCENTRAL website here. For more information, contact Margery Jacobson at mjacobson@LUNGevity.org.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Nuvalent announces positive topline pivotal data from ALKOVE-1 trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC

Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 phase I/II clinical trial. 
Drugs & Targets

FDA approves Hyrnuo for HER2-mutated NSCLC

FDA has approved Hyrnuo (sevabertinib), an oral, reversible, tyrosine kinase inhibitor, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account